To the full analysis
Buyback calculator for United Therapeutics
United Therapeutics stock: key metrics
UTHRUnited Therapeutics had an operating margin of 47.7% and a return on invested capital (ROIC) of 26.1% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 89.3% | 18.2% | 46.3% |
| 2007 | 89.4% | 3.0% | 9.4% |
| 2008 | 89.3% | −29.1% | −15.2% |
| 2009 | 87.7% | 7.0% | 5.3% |
| 2010 | 87.8% | 27.2% | 17.5% |
| 2011 | 88.0% | 42.8% | 29.3% |
| 2012 | 87.0% | 46.0% | 33.2% |
| 2013 | 88.3% | 26.2% | 15.6% |
| 2014 | 90.2% | 41.8% | 26.4% |
| 2015 | 95.3% | 47.7% | 44.5% |
| 2016 | 95.5% | 66.4% | 44.6% |
| 2017 | 93.9% | 47.2% | 24.2% |
| 2018 | 87.8% | 49.5% | 36.2% |
| 2019 | 91.9% | −12.9% | −7.2% |
| 2020 | 92.7% | 40.0% | 34.7% |
| 2021 | 92.7% | 33.0% | 28.2% |
| 2022 | 92.4% | 50.6% | 37.6% |
| 2023 | 88.9% | 50.9% | 42.3% |
| 2024 | 89.2% | 47.9% | 41.5% |
| 2025 | 87.9% | 47.7% | 41.9% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 36.1% | 12.8% | 15.5% |
| 2007 | 6.7% | 2.6% | 3.4% |
| 2008 | −8.4% | −17.0% | −4.9% |
| 2009 | 3.0% | 4.4% | 1.9% |
| 2010 | 12.0% | 19.0% | 7.4% |
| 2011 | 23.0% | 33.6% | 14.4% |
| 2012 | 27.8% | 34.2% | 18.7% |
| 2013 | 13.4% | 20.5% | 8.4% |
| 2014 | 26.9% | 43.8% | 18.0% |
| 2015 | 40.7% | 64.7% | 29.8% |
| 2016 | 38.3% | 97.7% | 30.7% |
| 2017 | 19.9% | 39.6% | 14.5% |
| 2018 | 21.1% | 41.0% | 17.3% |
| 2019 | −3.8% | −7.9% | −2.7% |
| 2020 | 15.2% | 21.2% | 11.2% |
| 2021 | 12.0% | 17.2% | 9.2% |
| 2022 | 15.2% | 26.8% | 12.0% |
| 2023 | 16.5% | 28.4% | 13.7% |
| 2024 | 18.5% | 29.8% | 16.2% |
| 2025 | 18.8% | 26.1% | 16.9% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 May 2022)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.